Wockhardt Limited
WOCKPHARMA
주식 순위
#4516
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
주가
$21.04
마지막 동기화: 2026-10-19
시가총액
$3.42B
변동 (1일)
-2.39%
변동 (1년)
38.07%
국가
IN
거래 Wockhardt Limited (WOCKPHARMA)
카테고리
Healthcare
Wockhardt Limited (WOCKPHARMA)의 P/S 비율
October 2026 기준 P/S 비율 TTM: 8.92
Wockhardt Limited의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 8.92입니다. 2024년 말 기준 P/S 비율은 3.05였습니다.
Wockhardt Limited의 P/S 비율 기록 (2004 ~ 2026)
매년 말 P/S 비율
| 연도 | P/S 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 8.92 | 20.16% |
| 2025 | 7.42 | 143.29% |
| 2024 | 3.05 | 264.90% |
| 2023 | 0.84 | -15.53% |
| 2022 | 0.99 | -46.30% |
| 2021 | 1.84 | 151.79% |
| 2020 | 0.73 | -44.52% |
| 2019 | 1.32 | -42.22% |
| 2018 | 2.28 | 6.29% |
| 2017 | 2.15 | -17.82% |
| 2016 | 2.62 | -47.40% |
| 2015 | 4.97 | 340.80% |
| 2014 | 1.13 | -73.70% |
| 2013 | 4.29 | 178.30% |
| 2012 | 1.54 | 50.46% |
| 2011 | 1.02 | 179.89% |
| 2010 | 0.37 | 1.87% |
| 2008 | 0.36 | -80.81% |
| 2007 | 1.87 | -22.86% |
| 2006 | 2.43 | -34.99% |
| 2005 | 3.73 | 10.06% |
| 2004 | 3.39 | 0.00% |
유사 기업 또는 경쟁사의 P/S 비율
| 회사 | P/S 비율 | P/S 비율 차이 | 국가 |
|---|---|---|---|
| 10.31 | 15.65% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 69.62% |
US
|
